Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

Femasys Inc. (FEMY) recently received 510(k) clearance from the FDA for FemChec, a diagnostic device for fallopian tube assessment. The device offers controlled delivery of contrast, confirming tubal status safely and efficiently. Femasys has achieved U.S. FDA clearance and Canadian regulatory approval for FemChec, a diagnostic solution designed for the controlled delivery of natural contrast during ultrasound evaluations of fallopian tubes. The device uses an alternating saline and air pattern to assist in ...